AI-designed “intrabodies” could unlock new treatments for Alzheimer’s, Parkinson’s and MND
Researchers at the University of Essex have used AI to design 'intrabodies,' which are small antibody fragments capable of functioning inside human cells. This breakthrough could lead to new treatments for neurodegenerative diseases like Alzheimer's and Parkinson's by targeting disease-related proteins directly.
Why it matters
This technology provides a novel pathway for addressing diseases that were previously difficult to treat because they originate inside the cell.
Researchers at the University of Essex have developed microscopic medicines that could pave the way for new approaches to treating neurodegenerative diseases such as Alzheimer's, Parkinson's, and motor neurone disease (MND).
Working with an international team, the scientists used artificial intelligence to create extremely small antibody fragments that can be produced directly inside human cells. Once there, the fragments can attach to proteins associated with disease.
Ordinary antibodies generally function outside cells. The newly redesigned fragments, called intrabodies, have instead been engineered to remain stable within cells, allowing them to target proteins involved in neurodegenerative conditions.
Electrical Charge Helps Antibodies Survive Inside Cells
The research was funded by the MND Association and led by Dr. Caitlin O'Shea and Dr. Gareth Wright from the School of Life Sciences. The team discovered that electrical charge is a key factor in determining whether antibody fragments can remain stable and functional inside cells.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in